Amphotericin B

Generic Name
Amphotericin B
Brand Names
Abelcet, Ambisome, Amphotec, Fungizone
Drug Type
Small Molecule
Chemical Formula
C47H73NO17
CAS Number
1397-89-3
Unique Ingredient Identifier
7XU7A7DROE
Background

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL...

Indication

Used to treat potentially life threatening fungal infections.

Associated Conditions
Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Associated Therapies
-

Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis

First Posted Date
2008-03-05
Last Posted Date
2009-04-03
Lead Sponsor
Banaras Hindu University
Target Recruit Count
400
Registration Number
NCT00628719
Locations
🇮🇳

Kala-azar Medical Research Center, Rambag Road, Muzaffarpur, India

Antimicrobial PK in Infants With Suspected or Confirmed Infection

First Posted Date
2007-06-26
Last Posted Date
2012-11-19
Lead Sponsor
Duke University
Target Recruit Count
450
Registration Number
NCT00491426
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

University of California at San Diego, La Jolla, California, United States

and more 3 locations

Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-05-01
Last Posted Date
2014-07-18
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
40
Registration Number
NCT00467883
Locations
🇫🇷

Hôpital Necker - Service des Maladies Infectieuses et Tropicales, Paris, France

🇫🇷

Necker Hospital, Paris, France

Intermittent Liposomal Amphotericin B Primary Prophylaxis

Phase 2
Conditions
First Posted Date
2007-03-23
Last Posted Date
2013-12-16
Lead Sponsor
Bayside Health
Target Recruit Count
60
Registration Number
NCT00451711
Locations
🇦🇺

The Alfred Hosptial, Melbourne, Victoria, Australia

🇦🇺

Box Hill Hospital, Eastern Health, Melbourne, Victoria, Australia

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

First Posted Date
2007-01-09
Last Posted Date
2023-10-16
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
20
Registration Number
NCT00419770
Locations
🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 4 locations

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

First Posted Date
2007-01-05
Last Posted Date
2012-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT00418951
Locations
🇺🇸

The University of Texas M D Anderson Cancer Center, Houston, Texas, United States

PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

Phase 4
Completed
Conditions
First Posted Date
2006-08-10
Last Posted Date
2015-07-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
30
Registration Number
NCT00362544
Locations
🇫🇷

Gilead Sciences, Paris, France

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Phase 4
Completed
Conditions
First Posted Date
2006-06-07
Last Posted Date
2015-07-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
30
Registration Number
NCT00334412
Locations
🇫🇷

Gilead Sciences, Paris, France

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-05-16
Last Posted Date
2010-02-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
34
Registration Number
NCT00326157
Locations
🇮🇹

Gilead Sciences, Milan, Italy

Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients

Phase 3
Terminated
Conditions
First Posted Date
2005-10-10
Last Posted Date
2008-12-17
Lead Sponsor
University of Pittsburgh
Target Recruit Count
12
Registration Number
NCT00235651
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath